Skip to Content


Meeting of the Advisory Committee on Immunization Practices

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document including its time on Public Inspection. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).


Notice of meeting.


In accordance with the Federal Advisory Committee Act, the CDC announces the following meeting of the Advisory Committee on Immunization Practices (ACIP). This meeting is open to the public, limited only by room seating. The meeting room accommodates 400. Time will be available for public comment.


The meeting will be held on October 24, 2018, 8:30 a.m. to 5:15 p.m., EDT, and October 25, 2018, 8:30 a.m. to 4:00 p.m. EDT.

The public is welcome to submit written comments in advance of the meeting. Comments should be submitted in writing by email to the contact person listed in FOR FURTHER INFORMATION CONTACT. The deadline for receipt is October 15, 2018.


CDC, 1600 Clifton Road NE, Tom Harkin Global Communications Center, Kent `Oz' Nelson Auditorium, Atlanta, GA 30329-4027.

The meeting will be webcast live via the World Wide Web; for instructions and more information on ACIP please visit the ACIP website:​vaccines/​acip/​index.html.

Start Further Info


Stephanie Thomas, ACIP Committee Management Specialist, CDC, NCIRD, telephone 404-639-8836, email

End Further Info End Preamble Start Supplemental Information


Purpose: The committee is charged with advising the Director, CDC, on the use of immunizing agents. In addition, under 42 U.S.C. 1396s, the committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding dosing interval, dosage, and contraindications to administration of vaccines. Further, under provisions of the Affordable Care Act, section 2713 of the Public Health Service Act, immunization recommendations of the ACIP that have been approved by the Director of the Centers for Disease Control and Prevention and appear on CDC immunization schedules must be covered by applicable health plans.

Matters to Be Considered: The agenda will include discussions on child/adolescent immunization schedule, adult immunization schedule, human papillomavirus vaccines, pneumococcal vaccines, Japanese encephalitis vaccines, zoster vaccine, Influenza vaccines, general recommendations, anthrax vaccine, hepatitis A vaccine, Pertussis vaccine, and meningococcal vaccines. A recommendation vote is scheduled for child/adolescent immunization schedule and adult immunization schedule. Agenda items are subject to change as priorities dictate. For more information on the meeting agenda visit​vaccines/​acip/​meetings/​meetings-info.html.

Public Comment: Written comments must include full name, address, organizational affiliation, email address of the speaker, topic being addressed and specific comments. Written comments must not exceed one single-spaced typed page with 1-inch margins containing all items above. Only those written comments received 10 business days in advance of the meeting will be included in the official record of the meeting. Public comments made in attendance must be no longer than 3 minutes and the person giving comments must attend the public comment session at the start time listed on the agenda. Time for public comments may start before the time indicated on the agenda. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Start Signature

Sherri Berger,

Chief Operating Officer, Centers for Disease Control and Prevention.

End Signature End Supplemental Information

[FR Doc. 2018-18184 Filed 8-22-18; 8:45 am]